Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Epithelial displacement into the lymphovascular space can be seen in breast core needle biopsy specimens.

Koo JS, Jung WH, Kim H.

Am J Clin Pathol. 2010 May;133(5):781-7. doi: 10.1309/AJCPQ0LEIOUTMSUD.

PMID:
20395526
2.

D2-40 expression by breast myoepithelium: potential pitfalls in distinguishing intralymphatic carcinoma from in situ carcinoma.

Rabban JT, Chen YY.

Hum Pathol. 2008 Feb;39(2):175-83. doi: 10.1016/j.humpath.2007.06.018.

PMID:
18206495
3.
4.

Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsy.

Meijnen P, Oldenburg HS, Loo CE, Nieweg OE, Peterse JL, Rutgers EJ.

Br J Surg. 2007 Aug;94(8):952-6.

PMID:
17440955
5.

Core biopsy diagnosis of ductal carcinoma in situ: an indication for sentinel lymph node biopsy.

Mittendorf EA, Arciero CA, Gutchell V, Hooke J, Shriver CD.

Curr Surg. 2005 Mar-Apr;62(2):253-7.

PMID:
15796952
6.

Tumor size as predictor of microinvasion, invasion, and axillary metastasis in ductal carcinoma in situ.

Maffuz A, Barroso-Bravo S, Nájera I, Zarco G, Alvarado-Cabrero I, Rodríguez-Cuevas SA.

J Exp Clin Cancer Res. 2006 Jun;25(2):223-7.

PMID:
16918134
7.

Predictors of residual invasive disease after core needle biopsy diagnosis of ductal carcinoma in situ.

Rutstein LA, Johnson RR, Poller WR, Dabbs D, Groblewski J, Rakitt T, Tsung A, Kirchner T, Sumkin J, Keenan D, Soran A, Ahrendt G, Falk JS.

Breast J. 2007 May-Jun;13(3):251-7.

PMID:
17461899
8.

Outcomes for women with ductal carcinoma-in-situ and a positive sentinel node: a multi-institutional audit.

Moore KH, Sweeney KJ, Wilson ME, Goldberg JI, Buchanan CL, Tan LK, Liberman L, Turner RR, Lagios MD, Cody Iii HS, Giuliano AE, Silverstein MJ, Van Zee KJ.

Ann Surg Oncol. 2007 Oct;14(10):2911-7. Epub 2007 Jun 28.

PMID:
17597346
10.

Extensive retraction artifact correlates with lymphatic invasion and nodal metastasis and predicts poor outcome in early stage breast carcinoma.

Acs G, Dumoff KL, Solin LJ, Pasha T, Xu X, Zhang PJ.

Am J Surg Pathol. 2007 Jan;31(1):129-40.

PMID:
17197929
11.

Is core needle biopsy superior to fine-needle aspiration biopsy in the diagnosis of papillary breast lesions?

Masood S, Loya A, Khalbuss W.

Diagn Cytopathol. 2003 Jun;28(6):329-34.

PMID:
12768640
12.

Loss of expression of the putative tumor suppressor NES1 gene in biopsy-proven ductal carcinoma in situ predicts for invasive carcinoma at definitive surgery.

Yunes MJ, Neuschatz AC, Bornstein LE, Naber SP, Band V, Wazer DE.

Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):653-7.

PMID:
12788170
13.

Significance of lymph vessel invasion identified by the endothelial lymphatic marker D2-40 in node negative breast cancer.

Arnaout-Alkarain A, Kahn HJ, Narod SA, Sun PA, Marks AN.

Mod Pathol. 2007 Feb;20(2):183-91. Epub 2007 Jan 5.

14.
15.
16.
17.

Histologic criteria and pitfalls in the diagnosis of lymphovascular invasion in radical prostatectomy specimens.

Kryvenko ON, Epstein JI.

Am J Surg Pathol. 2012 Dec;36(12):1865-73. doi: 10.1097/PAS.0b013e318262c3d0.

PMID:
23154772
18.

Nipple aspirate fluid cytology in breast carcinoma.

Krishnamurthy S, Sneige N, Thompson PA, Marcy SM, Singletary SE, Cristofanilli M, Hunt KK, Kuerer HM.

Cancer. 2003 Apr 25;99(2):97-104.

20.

Ductal carcinoma in situ: value of sentinel lymph node biopsy.

Sakr R, Barranger E, Antoine M, Prugnolle H, Daraï E, Uzan S.

J Surg Oncol. 2006 Oct 1;94(5):426-30. Review.

PMID:
16967457

Supplemental Content

Support Center